Natera (NTRA) Scheduled to Post Quarterly Earnings on Thursday

Natera (NASDAQ:NTRA) will post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Natera to post earnings of ($0.72) per share for the quarter. Natera has set its FY 2024 guidance at EPS.Parties that wish to register for the company’s conference call can do so using this link.

Natera (NASDAQ:NTRA) last announced its earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The business had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. On average, analysts expect Natera to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Natera Price Performance

NASDAQ:NTRA opened at $97.15 on Wednesday. The company has a current ratio of 4.10, a quick ratio of 3.96 and a debt-to-equity ratio of 0.37. Natera has a 12 month low of $36.90 and a 12 month high of $98.82. The firm has a market cap of $11.73 billion, a P/E ratio of -25.63 and a beta of 1.38. The stock has a 50 day moving average of $91.44 and a two-hundred day moving average of $70.46.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on NTRA. Canaccord Genuity Group upped their price objective on shares of Natera from $87.00 to $100.00 and gave the company a “buy” rating in a research note on Thursday, February 29th. Craig Hallum began coverage on shares of Natera in a research report on Monday, April 8th. They set a “buy” rating and a $117.00 price objective for the company. Piper Sandler boosted their target price on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a report on Wednesday, March 6th. Stephens restated an “overweight” rating and set a $78.00 price target on shares of Natera in a report on Tuesday, January 30th. Finally, StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a report on Wednesday, May 1st. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $86.40.

Insider Activity

In other news, insider Jonathan Sheena sold 447 shares of Natera stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $90.22, for a total transaction of $40,328.34. Following the completion of the sale, the insider now directly owns 347,731 shares of the company’s stock, valued at approximately $31,372,290.82. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Herm Rosenman sold 93,901 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $69.37, for a total transaction of $6,513,912.37. Following the completion of the sale, the director now owns 61,685 shares in the company, valued at approximately $4,279,088.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Jonathan Sheena sold 447 shares of the stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $90.22, for a total transaction of $40,328.34. Following the completion of the transaction, the insider now directly owns 347,731 shares in the company, valued at $31,372,290.82. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 380,750 shares of company stock valued at $31,864,820. 7.60% of the stock is currently owned by corporate insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.